Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
29 hedge funds and large institutions have $4.64M invested in Statera Biopharma, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 3 reducing their positions, and 4 closing their positions.
267% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 3
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
65% more capital invested
Capital invested by funds: $2.81M → $4.64M (+$1.83M)
26% more funds holding
Funds holding: 23 → 29 (+6)
97% less call options, than puts
Call options by funds: $1K | Put options by funds: $36K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$455K |
| 2 |
Renaissance Technologies
New York
|
+$271K |
| 3 |
State Street
Boston,
Massachusetts
|
+$169K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$157K |
| 5 |
BlackRock
New York
|
+$124K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$45K |
| 2 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$35.4K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$32K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$29K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$26.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
UBS Group
Zurich,
Switzerland
| – | -$45K | -19,470 | Closed |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| – | -$32K | -13,891 | Closed |
|
|
28
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$29K | -12,619 | Closed |
|
29
Wells Fargo
San Francisco,
California
| – | -$24 | -8 | -5% |
|
|
UB
30
UMB Bank
Kansas City,
Missouri
| – | +$15 | +5 | New |
|
31
Bank of America
Charlotte,
North Carolina
| – | +$428 | +145 | +145% |
|
STAB Hedge Fund Activity: Q4 2021 in Review
29 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q4 2021, worth a combined $4.64M — up 65% from $2.81M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new STAB positions and 4 closed out — a net gain of 6 holders — while 11 added to existing stakes and 3 trimmed.
The largest buyer was Eaton Vance Management, opening a new position worth an estimated $455K. The largest seller was UBS Group, exiting entirely with an estimated $45K sold.
- 29 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q4 2021, up from 23 in Q3 2021.
- Funds reported $4.64M of Statera Biopharma, Inc. Common Stock stock for Q4 2021, up 65% quarter-over-quarter.
- 10 funds opened new Statera Biopharma, Inc. Common Stock positions in Q4 2021 and 4 closed out, a net change of +6 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q4 2021 was Eaton Vance Management, an estimated $455K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q4 2021 was UBS Group, an estimated $45K sold.
Based on aggregated 13F filings for Q4 2021.